AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04941937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg/d QW
Study NCT04941937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100mg/d, Po. on day1-28
Study NCT04941937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: PO,Lenalidomide 25mg once daily from D1-21
Study NCT04941937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle, PO.
Study NCT04941937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
Study NCT05741450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 1 (monthly replacement)
Description: Monthly replacement spherical silicone hydrogel contact lens for 15 minutes
Study NCT05741450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 2 (daily disposable)
Description: Daily disposable spherical silicone hydrogel contact lens for 15 minutes
Study NCT05764057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)
Description: Dapagliflozin (10 mg per day; per os) on top of standard of care as recommended in current guidelines\* for 6 months (experimental group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended.
Study NCT06270251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBIT
Description: 8sessions of CBIT following a published treatment manual delivered over 10 weeks (the last two sessions are biweekly)~CBIT is a well-established behavioral treatment that is considered by the American Academy of Neurology to be the first-line intervention for tics.
Study NCT05586672 — intervention group
Intervention type: DEVICE
Intervention: EEG-HR
Description: Passation EEG-HR
Study NCT05586672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ADI-R
Description: Passation of ADI-R scale
Study NCT06365957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketone monoester supplementation
Description: Exogenous ketones are a class of ketone bodies that are ingested using nutritional supplements or foods. This class of ketone bodies refers to the three water-soluble ketones (acetoacetate, β-hydroxybutyrate, and acetone).
Study NCT06365957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise
Description: High-intensity interval exercise is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high-intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of lower-intensity movements. The exercise will be conducted on a computer-monitored cycle ergometer.
Study NCT06365957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise
Description: Moderate-intensity continuous exercise generally consists of 30-60 min of aerobic exercise at 64-76% peak heart rate, while interval training involves more intense bouts interspersed by recovery periods. The exercise will be conducted on a computer-monitored cycle ergometer.
Study NCT06365957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo will be the taste-matched water.
Study NCT05670028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypotensive Drugs and/or Vasoactive Drugs
Description: To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or vasoactive drugs (noradrenaline or dopamine).
Study NCT05670028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotensive Drugs and/or Vasoactive Drugs
Description: To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or vasoactive drugs (noradrenaline or dopamine).
Study NCT05586672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ADOS-2
Description: Passation of ADOS-2 scale
Study NCT05586672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IDE
Description: Passation of IDE scale
Study NCT05586672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MSEL
Description: Passation of MSEL scale
Study NCT05586672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dunn
Description: Passation of Dunn scale
Study NCT05343234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tree different placebo drugs with tree different names and scheduled will be given
Study NCT05764057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo daily on top of standard of care as recommended in current guidelines\* for 6 months (control group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended.
Study NCT05292066 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine Tablets,
Description: Duloxetine is an FDA-approved medication used to treat the major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain. It is taken by mouth. It is a serotonin-norepinephrine reuptake inhibitor.~Pregabalin is an FDA approved, sold under the brand name Lyrica. it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,
Study NCT05292066 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin Tablets
Description: Pregabalin is an FDA approved, it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,
Study NCT04743960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Time-of-day of parenteral nutrition provision
Description: Parenteral nutrition will be provided during the nighttime followed by daytime.
Study NCT05820555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timed evening technology and digital media use (tablet use)
Description: timing of children's evening tablet device use relative to bedtime
Study NCT05273450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline Information with Reinforcement
Description: The intervention arm involves direct referral to the Ohio Tobacco Quitline, with up to two brief follow-up telephone calls from the research team to elicit motivation to quit, emphasize benefits of calling the quitline, encourage use and address concerns. Participants are surveyed at baseline and at 3-month follow-up to assess awareness and use of the quitline.
Study NCT05820555 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: no technology and digital media use (screen media use)
Description: no screen media use relative to bedtime (Tablets, computers, TV, moble devices, smart phone)
Study NCT02772081 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LISA combination product (Curosurf+catheter CHF6440)
Description: Curosurf administration through brief insertion of a thin catheter into the trachea
Study NCT02772081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curosurf through conventional administration (endotracheal tube)
Description: Curosurf through conventional administration (endotracheal tube), followed by rapid extubation
Study NCT05164042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic CD19 CAR-T cells
Description: infusion of allogeneic CD19 CAR-T cells
Study NCT05312398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: I LINE:~- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter~II LINE:~- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line~THIRD LINE:~- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line
Study NCT05312398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: I LINE:~- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter
Study NCT05312398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: II LINE:~- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line
Study NCT05312398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: III LINE:~- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line
Study NCT06304506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross sectional study
Description: Physiological testing, Sampling of blood and abdominal adipose tissue and respiratory measurements at rest and during exercise
Study NCT06201117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preparatory information for ICU stay
Description: Preparatory information for ICU stay after cardiac surgery via 12-minute digital media
Study NCT06201117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual information
Description: Preoperative information that is given to patients before having cardiac surgery
Study NCT06201117 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual information
Description: Preoperative information that is given to patients before having cardiac surgery
Study NCT05153044 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: severe acute respiratory syndrome CoV-2 serology
Description: diagnostic serology of severe acute respiratory syndrome-CoV-2 infection performed during the inclusion visit Regarding follow-up visits, only seropositive patients will be called for sampling, for serological follow-up at 3 months then 6 months.
Study NCT04899414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, azacytidine, Pegaspargase, Tislelizumab
Description: Dexamethasone 40mg intravenously daily on day 1-4; azacytidine 100mg intravenously daily on day 1-5; Pegaspargase 3750 IU intravenously daily on day 1； Tislelizumab 200 mg IV on Day 1 of each 21-day as a cycle.
Study NCT06120036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kybella
Description: Injection into the cutaneous Neurofibromas lesion.
Study NCT06120036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asclera
Description: Injection into the cutaneous Neurofibromas lesion.
Study NCT05766475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ROSE Program: In Person
Description: In-person preventative intervention for postpartum depression that includes content on building social support and communication skills in relationships, navigating the role transition to motherhood, and learning about signs and symptoms of depression after delivery.
Study NCT05766475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ROSE Program: Virtual
Description: Virtual ROSE covers the same content (e.g. improving social support and communication) and is delivered by the same facilitators as the in-person intervention via telehealth.
Study NCT05160831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: Human umbilical cord mesenchymal stem cell injection is applied for treating knee OA patients.
Study NCT06055816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar and Envafolimab
Description: Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
Study NCT05077670 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary vein electrical isolation
Description: Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy.
Study NCT06441292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AI-assisted
Description: utilize advanced deep learning models that integrate multi-modal image fusion from multi-parameter ultrasound and MRI to guide the biopsy process
Study NCT06441292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-AI-assisted
Description: undergo standard prostate biopsy procedures without additional technological assistance
Study NCT06349135 — intervention group
Intervention type: PROCEDURE
Intervention: Open Reduction & Internal Fixation
Description: Open Reduction \& Internal Fixation of Mandibular fracture either through intraoral or extraoral approaches.
Study NCT04186247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Weeks 4-12: 7.5 mg/kg azithromycin once daily (500 mg/day maximum) for five consecutive days/ week for 4 weeks, and 3 times a week for the following 4 weeks
Study NCT04186247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Weeks 4-12: 20 mg/kg/day of metronidazole (10 mg/kg twice daily to a maximum of 1000 mg/day) for 8 weeks
Study NCT04186247 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: SOC induction therapy is nutritional therapy (Crohn's disease exclusion diet + partial enteral nutrition) for up to 12 weeks. Induction therapy is as assigned by the treating gastroenterologist prior to study entry.
Study NCT04186247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: SOC induction therapy is nutritional therapy (Crohn's disease exclusion diet + partial enteral nutrition) for up to 12 weeks. Induction therapy is as assigned by the treating gastroenterologist prior to study entry.
Study NCT05364736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Highland barley β-glucan dietary supplement
Description: 100 mL oral liquid mainly containing highland barley β-glucan once daily for 12 weeks
Study NCT05364736 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controls
Description: Placebo with a similar appearance and taste to highland barley β-glucan supplement
Study NCT05077670 — intervention group
Intervention type: DEVICE
Intervention: Atrial substrate mapping
Description: Electro-anatomical maps will be performed with CARTO navigation system with multi-electrode catheters.
Study NCT06375785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago-based (slow rhythmic) exercise group
Description: Slow Rhythmic Exercises (Otago based) A.Strength training~1. Knee flexion and extension~2. Ankle dorsiflexion and plantar flexion~3. Toes flexion and extension~4. Hip abduction and adduction B. Balance training~1. Stepping backwards, walking and turning 2.Side walking 3. Octet walking 4.Tandem walking 5. Standing up from a sitting position
Study NCT06375785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LSVT BIG-based (large amplitude) exercise group
Description: Large Amplitude Exercises (based on LSVT-BIG)~1. Bending towards the floor and rising towards the ceiling (opening) while sitting~2. While sitting, turn to the right and left with the body and reach out~3. Sit down~4. Step forward~5. Sidestepping~6. Stepping back~7. Step forward and extend arm towards the ceiling~8. Step sideways and extend arm towards the ceiling~9. Walking with big steps~10. Turning from right to left and left to right while walking
Study NCT05569876 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Controlled hypoglycemic state
Description: Voice sampling is performed in different glycemic states (euglycemia and hypoglycemia).
Study NCT06183879 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryoballoon pulmonary vein isolation (Medtronic 4th gen balloon)
Description: Standard of care cryoballoon pulmonary vein isolation with Medtronic 4th gen balloon
Study NCT06183879 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryoballoon pulmonary vein isolation (Boston 2nd gen balloon)
Description: Standard of care cryoballoon pulmonary vein isolation with Boston 2nd gen balloon
Study NCT06578143 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered in capsules (500 mg each). Participants are instructed to take the capsules twice daily, with two capsules per dose, after meals. The duration of the intervention is 6 weeks.
Study NCT05547529 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.
Description: Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.
Study NCT05547529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
Description: Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
Study NCT02962804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg per IV infusion over 60 minutes every 14 days (+/- 2 days) until disease progression or participant withdrawal from study
Study NCT02962804 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation to at least 1 site (up to 3) of primary or metastasis, 5 fractions - delivered over 2 weeks, starting 1-3 days post-nivolumab administration. Recommended dose range is 6 Gy-12 Gy per fraction.
Study NCT05823844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant (Belsomra™) is an orexin receptor antagonist that will be administered as 2 tablets (10mg each) for a starting dose of 20mg. If the dose is not well tolerated (e.g., daytime sleepiness), then the dose may be decreased to 10 mg of Suvorexant.
Study NCT05823844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pill will look identical to Suvorexant and will be taken as 2 tablets.
Study NCT05229796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 mg Tab
Description: The Empagliflozin 10 mg Tab were administered orally. The plasma concentrations of empagliflozin were determined using an HPLC-MS/MS method. Tolerability and safety were assessed throughout the study. This study included 26 subjects, 26 in each fasting and fed group.
Study NCT06578143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synbiotics
Description: Synbiotics is administered in capsules (500 mg each). Participants are instructed to take the capsules twice daily, with two capsules per dose, after meals. The duration of the intervention is 6 weeks.
Study NCT05478668 — intervention group
Intervention type: OTHER
Intervention: visual analog scale
Description: In all patients, the assessment of anesthetic risk was carried out according to the ASA scale. The basic tool for pain intensity research was a visual analog scale. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the Didier Bouhassiraa neuropathic pain diagnostic questionnaire. Study of the presence of an acute stress reaction The Hospital Anxiety and Depression Scale. Research on the presence of post-traumatic stress disorders was carried out using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
Study NCT05132517 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Kölner Neuropsychologische Screening für Schlaganfall-Patienten
Description: The cognitive state of the patient is measure by the Kölner Neuropsychologische Screening (KöpSS) and by the Mini Mental Status Test (MMST). The MMST is a popular often used test, which makes comparisons to other international studies possible. However, even though this test was specifically designed for stroke patients, it has a limited sensibility. Thus the KöpSS is being used as an additional test demonstrating satisfactory sensibility and specificity. It is suitable for acute and subacute strokes and covers all stroke relevant domains.